Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -29.01
- Piotroski Score 4.00
- Grade Outperform
- Symbol (ATRA)
- Company Atara Biotherapeutics, Inc.
- Price $8.13
- Changes Percentage (0.68%)
- Change $0.06
- Day Low $8.01
- Day High $8.66
- Year High $45.75
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/29/2024
- Fiscal Year End N/A
- Average Stock Price Target $10.50
- High Stock Price Target $18.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.12
- Trailing P/E Ratio -0.25
- Forward P/E Ratio -0.25
- P/E Growth -0.25
- Net Income $-2,761,260,000
Income Statement
Quarterly
Annual
Latest News of ATRA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
15 killed after a landslide struck an illegal gold mine on Indonesia's Sumatra island
A landslide hit an illegal gold mining site in Indonesia's Sumatra, leaving 15 dead and many missing. The incident occurred in Solok district, West Sumatra province. Efforts are ongoing to rescue thos...
By AP NEWS | 3 days ago -
Dynatrace (DT): Dominating the Market with AI and Cloud Innovations
Insider Monkey recently highlighted the 16 Best Mid Cap Growth Stocks, focusing on Dynatrace, Inc. in comparison. Amid market dynamics and potential rate cuts, analysts foresee impacts on financial se...
By Yahoo! Finance | 1 week ago -
Dynatrace Stock Earns RS Rating Upgrade
Dynatrace (DT) stock's RS Rating increased to 73, below the ideal 80. A strong RS Rating of 80+ often indicates potential growth. Monitoring Dynatrace's price strength is essential for potential inves...
By Investor's Business Daily | 1 week ago